Compare Comfort Systems USA Inc (FIX) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Comfort Systems USA Inc vs Tango Therapeutics Inc. — how do they compare? Comfort Systems USA Inc trades at $1,495.5 (market cap $54.26B), while Tango Therapeutics Inc. trades at $22.3 (market cap $3.74B). The key difference: Comfort Systems USA Inc is far larger — about 14.5× Tango Therapeutics Inc.'s market cap, and Comfort Systems USA Inc pays a 0.23% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Comfort Systems USA Inc for 42 Days and Tango Therapeutics Inc. for 0 Days on average.
| FIX | TNGX | |
|---|---|---|
Market Cap | $54.26B | $3.74B |
Volume | 449,972 | 3,438,781 |
Sector | Industrials | Health |
52-Week High | $2.07K | $32.90 |
52-Week Low | $790.72 | $7.50 |
Typical Hold Time | 42 Days | 0 Days |
Enterprise Value | $52.73B | $2.76B |
Dividend Yield | 0.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Comfort Systems USA (FIX) trades at $1,626.64, down 0.7% on the day, with a bearish technical signal despite strong fundamental performance. The company has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $12.53 exceeding expectations by 20%. Revenue growth remains robust, projected to increase from $9.1B in 2025 to $11.2B in 2026, while net profit margins improved from 11.23% to 12.77%.
The stock presents a compelling growth story with strong exposure to data center and infrastructure markets, though elevated valuation multiples (P/E 37.94, P/S 4.85) and technical bearish signals warrant caution. Analyst consensus remains positive with a $2,080 price target representing 28% upside potential, supported by institutional buying interest and strategic acquisitions like the $206M Hunt Electric deal.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Comfort Systems USA Inc
Comfort Systems USA is a premier provider of mechanical and electrical contracting services. It specializes in HVAC, plumbing, and energy management solutions for commercial and industrial facilities.
Read more on FIX →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
